PKO Investment Management Joint Stock Co Invests $625,000 in Cencora, Inc. $COR

PKO Investment Management Joint Stock Co purchased a new stake in shares of Cencora, Inc. (NYSE:COR) in the third quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 2,000 shares of the company’s stock, valued at approximately $625,000.

Several other hedge funds have also bought and sold shares of the business. Baader Bank Aktiengesellschaft boosted its holdings in Cencora by 318.5% in the second quarter. Baader Bank Aktiengesellschaft now owns 4,336 shares of the company’s stock worth $1,300,000 after acquiring an additional 3,300 shares in the last quarter. Focus Partners Wealth increased its holdings in shares of Cencora by 25.8% during the first quarter. Focus Partners Wealth now owns 5,715 shares of the company’s stock valued at $1,589,000 after acquiring an additional 1,171 shares in the last quarter. Acadian Asset Management LLC raised its position in shares of Cencora by 947.5% in the 2nd quarter. Acadian Asset Management LLC now owns 257,082 shares of the company’s stock worth $77,069,000 after purchasing an additional 232,539 shares during the last quarter. Fiduciary Alliance LLC purchased a new position in shares of Cencora in the 2nd quarter worth about $262,000. Finally, Synergy Asset Management LLC bought a new position in Cencora in the 3rd quarter worth about $10,093,000. Institutional investors own 97.52% of the company’s stock.

Cencora Stock Performance

Shares of NYSE COR opened at $345.53 on Wednesday. The firm’s 50-day moving average price is $349.93 and its 200-day moving average price is $319.10. Cencora, Inc. has a 52-week low of $235.77 and a 52-week high of $377.54. The company has a market cap of $67.03 billion, a PE ratio of 43.46, a PEG ratio of 1.63 and a beta of 0.66. The company has a quick ratio of 0.55, a current ratio of 0.90 and a debt-to-equity ratio of 4.32.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, beating analysts’ consensus estimates of $3.79 by $0.05. Cencora had a net margin of 0.48% and a return on equity of 227.15%. The company had revenue of $83.73 billion for the quarter, compared to the consensus estimate of $83.36 billion. During the same quarter in the prior year, the firm earned $3.34 earnings per share. The firm’s revenue for the quarter was up 5.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. As a group, analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, December 1st. Stockholders of record on Friday, November 14th were paid a $0.60 dividend. This is an increase from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date was Friday, November 14th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. Cencora’s dividend payout ratio (DPR) is 30.19%.

Analyst Ratings Changes

Several analysts recently commented on the stock. Mizuho increased their price objective on shares of Cencora from $340.00 to $380.00 and gave the company an “outperform” rating in a research report on Thursday, November 6th. Barclays initiated coverage on shares of Cencora in a research note on Monday, December 8th. They issued an “overweight” rating and a $400.00 target price on the stock. Wells Fargo & Company increased their price target on shares of Cencora from $354.00 to $405.00 and gave the company an “overweight” rating in a report on Tuesday, November 11th. UBS Group raised their price target on shares of Cencora from $380.00 to $415.00 and gave the company a “buy” rating in a research report on Friday, November 7th. Finally, Evercore ISI set a $400.00 price objective on Cencora and gave the company an “outperform” rating in a research report on Thursday, November 6th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $381.42.

Insider Transactions at Cencora

In related news, CEO Robert P. Mauch sold 5,097 shares of Cencora stock in a transaction on Monday, October 20th. The stock was sold at an average price of $326.80, for a total value of $1,665,699.60. Following the completion of the sale, the chief executive officer owned 37,940 shares of the company’s stock, valued at $12,398,792. The trade was a 11.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Elizabeth S. Campbell sold 3,351 shares of the stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $342.10, for a total value of $1,146,377.10. Following the completion of the transaction, the executive vice president directly owned 23,891 shares in the company, valued at approximately $8,173,111.10. This represents a 12.30% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 20,317 shares of company stock worth $7,009,260 in the last ninety days. Insiders own 10.80% of the company’s stock.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.